J1952 HCPCS code: Leuprolide injectable, camcevi, 1 mg
J1952 is the HCPCS Level II code for leuprolide injectable, camcevi, 1 mg. In 2024 Medicare paid an average of $44.84 per service for J1952 across 537,148 services. Its Medicare coverage code is C (Carrier judgment): Coverage is decided by the Medicare contractor (MAC) case by case. The NCCI unit limit is 42 per day on outpatient hospital claims. Medicare volume rose 1108% from 2022 to 2024 (44,451 to 537,148 services). In 2024, about 1,262 clinicians billed Medicare for J1952 for 9,037 beneficiaries; Illinois, New York, California accounted for 30% of services.
Code details
| Field | Value |
|---|---|
| Section | J codes — Drugs administered other than oral method |
| Coverage code | C — Carrier judgment |
| Pricing indicator | 51 — Drug or biological (priced per ASP/average sales price rules) |
| BETOS category | O1D — Chemotherapy |
| Added | 2022-01-01 |
| Last action effective | 2022-10-01 |
Who bills J1952 (2024)
| Measure | Value |
|---|---|
| Clinicians billing (by place of service) | 1,262 |
| Medicare beneficiaries | 9,037 |
| States with claims | 37 |
| Share of services in top 3 states (Illinois, New York, California) | 30% |
Counts only. Supplier and clinician names, contact lists and state-by-state detail are in Caduvo.
Medicare utilization for J1952, 2022–2024
| Year | Services | Beneficiaries | Avg. allowed | Avg. paid |
|---|---|---|---|---|
| 2022 | 44,451 | 1,084 | $101.68 | $81.03 |
| 2023 | 338,316 | 6,341 | $81.24 | $64.67 |
| 2024 | 537,148 | 9,037 | $56.48 | $44.84 |
States with the most J1952 services (2024)
| State | Services | Avg. paid |
|---|---|---|
| Illinois | 58,608 | $44.87 |
| New York | 52,206 | $45.07 |
| California | 51,096 | $44.73 |
| Virginia | 49,026 | $44.60 |
| Indiana | 33,770 | $44.75 |
NCCI unit limits (MUE)
| Claim type | Max units per day | Rationale |
|---|---|---|
| outpatient hospital claims | 42 | Prescribing Information |
| practitioner claims | 42 | Prescribing Information |
Medicare policy articles for this code
- A52453: Billing and Coding: Luteinizing Hormone-Releasing Hormone (LHRH) Analogs (Wellpoint Federal (MAC - Part A, MAC - Part B))
- A59160: Billing and Coding: Luteinizing Hormone-Releasing Hormone (LHRH) Analogs (Palmetto GBA (MAC - Part A, MAC - Part B))
Covered diagnoses (246 ICD-10-CM codes)
The diagnoses most often listed as covered in the policy articles above:
| ICD-10-CM | Diagnosis | Articles listing it |
|---|---|---|
| C08.0 | Malignant neoplasm of submandibular gland | 2 |
| C08.1 | Malignant neoplasm of sublingual gland | 2 |
| C48.1 | Malignant neoplasm of specified parts of peritoneum | 2 |
| C48.8 | Malignant neoplasm of overlapping sites of retroperitoneum and peritoneum | 2 |
| C50.011 | Malignant neoplasm of nipple and areola, right female breast | 2 |
| C50.012 | Malignant neoplasm of nipple and areola, left female breast | 2 |
| C50.021 | Malignant neoplasm of nipple and areola, right male breast | 2 |
| C50.022 | Malignant neoplasm of nipple and areola, left male breast | 2 |
| C50.111 | Malignant neoplasm of central portion of right female breast | 2 |
| C50.112 | Malignant neoplasm of central portion of left female breast | 2 |
Showing 10 of 246. The full list, non-covered diagnoses and CSV export are in Caduvo.
What changed for J1952
- 2022-01-01: J1952 added to HCPCS Level II
- Next scheduled CMS quarterly update (HCPCS and DMEPOS fee schedule): 2027-01-01
Frequently asked questions
What is HCPCS code J1952?
J1952 is the HCPCS Level II code for leuprolide injectable, camcevi, 1 mg. Short descriptor: "Leuprolide inj, camcevi, 1mg".
How much does Medicare pay for J1952?
In 2024, the average Medicare payment was $44.84 per service (average allowed $56.48).
Does Medicare cover J1952?
Coverage code C — Carrier judgment. Coverage is decided by the Medicare contractor (MAC) case by case.
Which diagnoses support coverage for J1952?
Medicare policy articles that cite J1952 list 246 covered ICD-10-CM diagnosis codes across 2 articles. The most cited include C08.0 (Malignant neoplasm of submandibular gland), C08.1 (Malignant neoplasm of sublingual gland), C48.1 (Malignant neoplasm of specified parts of peritoneum). A listed diagnosis is necessary but not sufficient; the policy's other criteria still apply.
How many units of J1952 can be billed per day?
42 on outpatient hospital claims; 42 on practitioner claims (NCCI medically unlikely edits).
Related J19 codes
- J1920 — Injection, labetalol hydrochloride, 5 mg
- J1921 — Injection, labetalol hydrochloride (hikma), not therapeutically equivalent to j1920, 5 mg
- J1930 — Injection, lanreotide, 1 mg
- J1931 — Injection, laronidase, 0.1 mg
- J1932 — Injection, lanreotide, (cipla), 1 mg
- J1938 — Injection, furosemide, 1 mg
- J1939 — Injection, bumetanide, 0.5 mg
- J1940 — Injection, furosemide, up to 20 mg
- J1941 — Injection, furosemide (furoscix), 20 mg
- J1942 — Injection, aripiprazole lauroxil, 1 mg
- J1943 — Injection, aripiprazole lauroxil, (aristada initio), 1 mg
- J1944 — Injection, aripiprazole lauroxil, (aristada), 1 mg
Building a device that would bill under a code like this? Caduvo matches a device description to HCPCS/CPT codes, Medicare coverage and payment, and the FDA pathway in one report.
Next steps
- Run a reimbursement report for a device billed under J1952
- Watch J1952 for fee, coverage and descriptor changes
- Build a full Medicare revenue model for J1952
Compiled by Caduvo from public CMS (Medicare) records, HCPCS release October 2026. Fees are Medicare allowables, not commercial rates. Not reviewed or endorsed by CMS. Not billing or legal advice. Report an error. Data and corrections policy.